Navigation Links
Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
Date:11/21/2008

er major companies.

Based on our transforming scientific discoveries and sound business model, Intellect is on track to become a major player in the discovery and development of drugs to treat AD, a devastating disease that is rapidly growing in prevalence and for which there are currently no efficacious disease-modifying treatments. We have made excellent progress towards achieving our goal for our company even in the face of a truly daunting financial market.

Financially, we continue to vigorously pursue various options to provide the funding necessary to fully realize the aforementioned strategy. We thank you for your patience and understanding as we go through this process.

As we move forward to realize the potential of our discoveries, we are grateful for the support and confidence of all of our shareholders. Be assured that we are steadfast in the pursuit of our goal to build a company that makes significant contributions to the public health and that brings outstanding financial rewards to its investors.

Thank you for your continued interest and support of Intellect Neurosciences, as we work to develop new drugs aimed at slowing or preventing Alzheimer's disease.

Sincerely,

Daniel Chain, Ph.D.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of AD and other disorders. The Company has a broad proprietary immunotherapy platform for both passive and active immunization against AD. Also, Intellect has completed Phase I clinical trials for OXIGON(R), which has the potential to be used as a treatment for AD and other serious disorders.

For additional information, please visit
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
10. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate
11. IC Sciences Announces Launch of ICS Advisory Services Intellectual Property Platforms Available Through ICSciences Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 2015 Research and Markets ( ... "Bone Morphogenetic Proteins Market (Types : rhBMP-2 ... Oral - Maxillofacial) - Global Industry Analysis, Size, ... report to their offering. The ... on the types of recombinant BMPs, applications, and ...
(Date:5/20/2015)... Winston-Salem, NC (PRWEB) May 20, 2015 ... Winston-Salem, NC based not-for-profit organization, is pleased to announce ... International Clinical Trials Day. These donations represent the effort ... a study at the GGI partner sites in 2014. ... and highlight the greater good of clinical trial participation, ...
(Date:5/20/2015)... May 20, 2015 CD-adapco, the largest ... today announced the release of DARS v2.10. DARS is ... management and analyses of chemical reactions. DARS v2.10, which ... features a library generation functionality that makes it possible ... operating conditions for simulations with STAR-CD® and STAR-CCM+®. , ...
(Date:5/20/2015)... , May 20, 2015 ... the addition of the  "Global Medical Robotics Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , According ... Outlook 2018, is currently worth US$ 3.2 Billion ... by 2018. The report provides an overview of ...
Breaking Biology Technology:Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2The Greater Gift Initiative Donates over 10,000 Vaccines in Honor of International Clinical Trials Day 2CD-adapco’s New DARS v2.10 Release Enhances User Capabilities 2CD-adapco’s New DARS v2.10 Release Enhances User Capabilities 3Global Medical Robotics Market Outlook 2018 2Global Medical Robotics Market Outlook 2018 3
... 8 Brinks Hofer Gilson & Lione, one ... United States, is pleased to,announce that William F. ... Group, one of the largest nanotechnology practices in ... 10 intellectual property lawyers,influencing the field of Nanotechnology ...
... Inverness Medical,Innovations, Inc. (Amex: IMA ), a ... solutions, is featuring its,new TB diagnostic test, the ... 2008)., The test, which was introduced to ... needed aid in the diagnosis of Mycobacterium,tuberculosis (TB) ...
... MGT Capital Investments,Inc. (Amex: MGT ), ... Technology ("HCIT") sector, today reported financial results,for the ... an update on,strategic milestones., Tim Paterson-Brown, MGT ... half of 2008 reflect continued progress in the ...
Cached Biology Technology:William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology 2Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 2MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 3MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 4MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments 5
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Drug Administration (FDA) today issued a public health advisory ... to new safety information concerning an unapproved (i.e., "off-label") ... drugs are approved for the treatment of schizophrenia and ... behavioral disorders in elderly patients with dementia have shown ...
... versatile microorganisms ?a bacterium called Pseudomonas putida ?could ... the destruction of the chemical weapon mustard, write ... Biotechnology (http://www.interscience.wiley.com/jctb) this month. , At 40,000 tonnes, ... warfare agents (CWAs). The country faces a race ...
... traveler's diarrhea cases among U.S. travelers to Mexico ... cause of nonbacterial gastroenteritis outbreaks usually associated with ... researchers at the Johns Hopkins Bloomberg School of ... found that the longer travelers stayed at their ...
Cached Biology News:FDA Warns About Antipsychotic Drugs and Elderly 2Could microbes solve Russia's chemical weapons conundrum? 2Norovirus found to cause traveler's diarrhea 2
... 1. 3500 V, 400 mA, 200 W ... linear voltage ramp modes.Linear voltage ramp mode ... strips quickly without danger of overheating.Volt-hour and ... thickness, sample ionic strength, and temperature.Stores and ...
Human Aminopeptidase P1/XPNPEP1 Affinity Purified PAb Protein Family: Aminopeptidases, Metalloproteases...
Template and primers for preparation of internal control spots...
Cross reactivity to St. Louis encephalitis (MSI-7) is determined by ELISA....
Biology Products: